Next Science Sets New Date for Capital Return Amid Delisting Plans

Next Science Adjusts Capital Return Timing

Next Science Limited (ASX – NXS), a company known for its innovative medical technology solutions, has announced a change to the payment date for its previously declared cash return of capital. Originally scheduled for an earlier date, the payment will now be made on Tuesday, 10 February 2026. This adjustment comes shortly after the company completed a significant corporate milestone; the sale of substantially all its assets to OSARTIS GmbH, a Demetra company, in mid-September 2025.

Context of the Asset Sale and Delisting

The asset sale marked a pivotal moment for Next Science, effectively transitioning the company out of its operational phase. Following this transaction, Next Science has formally applied to the Australian Securities Exchange (ASX) to be removed from the official list, signalling an impending delisting. This move typically reflects a company’s strategic shift, often after divesting core assets or restructuring.

Implications for Shareholders

For shareholders, the capital return represents a final distribution of value following the asset sale. The amendment to the payment date, while not elaborated upon in detail, may reflect administrative or regulatory considerations linked to the delisting process. Importantly, the company has confirmed that all other terms of the capital return remain unchanged, providing some certainty amid the transition.

Looking Ahead

Next Science’s announcement includes a standard caution regarding forward-looking statements, reminding investors of the inherent risks and uncertainties involved. As the company moves toward delisting, stakeholders will be watching closely to understand the full implications for remaining shareholder value and any residual corporate activities. The market will also be attentive to how the timing of the capital return aligns with regulatory approvals and final closure of the company’s affairs on the ASX.